- Tardive dyskinesia (TD) is a neurological disorder caused by long-term use of antipsychotic medications, characterized by involuntary, repetitive movements, primarily affecting the face and tongue
- The market growth is primarily driven by increasing prevalence of psychiatric disorders such as schizophrenia and bipolar disorder, along with rising awareness and early diagnosis of TD
- North America is expected to dominate the Tardive Dyskinesia Treatments market with a market share of estimated 45.05%, driven, by high prevalence of psychiatric disorders, advanced healthcare infrastructure, and strong availability of FDA-approved therapies such as valbenazine and deutetrabenazine
- Asia-Pacific is expected to be the fastest growing region in the tardive dyskinesia treatment market during the forecast period due to increasing mental health awareness, improving access to healthcare, and a growing patient population
- Vesicular Monoamine Transporter 2 (VMAT 2) segment is expected to dominate the market with a market share of 55.05% due to its proven efficacy of VMAT2 inhibitors, such as valbenazine and deutetrabenazine, in reducing symptoms of tardive dyskinesia. These drugs are specifically designed to target the underlying neurochemical imbalance, offering better symptom management and fewer side effects compared to traditional treatments
